Infect Chemother.  2012 Dec;44(6):485-490. 10.3947/ic.2012.44.6.485.

Rifampin-resistant Relapsed Tuberculosis Confirmed by Molecular Technique

• Moon SM
• Lee SO
• Choi SH
• Kim YS
• Woo JH
• Kim SH

• KMID: 1806939
• DOI: http://doi.org/10.3947/ic.2012.44.6.485

Abstract

Recurrent tuberculosis can be caused by a relapse of the original infecting strain, a reinfection with a new strain of Mycobacterium tuberculosis or a paradoxical response associated with the anti-tuberculosis treatment. A drug susceptibility test is important when evaluating recurrent tuberculosis but a conventional microbiological test may be unavailable or unsuccessful. Recently, direct molecular testing as a line probe assay (GenoType(R) MTBDRplus, Hain Lifescience GmbH, Nehren, Germany) has shown promising results for the diagnosis or treatment of drug-resistant tuberculosis. We present two cases of rifampin-resistant, relapsed tuberculosis that were confirmed using a molecular technique.

Keyword

Mycobacterium tuberculosis; Rifampin; Drug resistance

MeSH Terms

Drug Resistance
Mycobacterium tuberculosis
Recurrence
Rifampin
Sprains and Strains
Tuberculosis
Tuberculosis, Multidrug-Resistant
Rifampin

Reference

1. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ. Tuberculosis Trials Consortium. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004. 170:1360–1366.

2. . A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis. 1982. 126:460–462.

3. . Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. 1987. 136:1339–1342.

4. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003. 167:603–662.

5. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005. 171:1430–1435.

6. Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007. 45:4064–4066.

7. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004. 170:1124–1130.

8. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, Yanova GV, Strelis AK. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis. 2004. 39:1321–1328.

9. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000. 283:2537–2545.

10. Joh JS, Lee CH, Lee JE, Park YK, Bai GH, Kim EC, Han SK, Shim YS, Yim JJ. The interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results. J Korean Med Sci. 2007. 22:26–29.

11. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005. 25:564–569.

12. Han MD, Im JS, Yim J, Oh DK. A Study on the drug susceptibility test of multi-drug resistant tuberculosis patients. Korean J Epidemiol. 2008. 30:301–308.

13. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn. 2006. 6:423–432.

14. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.

15. Yoon NB, Lee SW, Park SM, Jeong IH, Park SY, Han SY, Lee YR, Jung JK, Kim JM, Kim SY, Um SJ, Lee SK, Son C, Hong YH, Lee KN, Roh MS, Kim KH. The current status of multidrug-resistant tuberculosis in one tertiary hospital in Busan, 2005~2009. Tuberc Respir Dis. 2011. 71:120–125.

16. Cho OH, Park KH, Park SY, Moon SM, Chong YP, Kim MN, Lee SO, Choi SH, Woo JH, Kim YS, Kim SH. Drug-resistant extrapulmonary tuberculosis. Infect Chemother. 2011. 43:258–261.

17. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993. 341:647–650.

18. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995. 8:496–514.

19. Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci. 2004. 9:975–994.

20. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2005. 5:62.

21. Wilson ML. Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance. Clin Infect Dis. 2011. 52:1350–1355.

22. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2009. 47:1767–1772.

23. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010. 363:1005–1015.

24. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007. 45:2635–2640.

25. Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2008. 12:1456–1460.

26. Huang WL, Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009. 47:2520–2524.

27. Jeong TD, An D, Sung H, Chi HS, Kim MN, Shim TS. Evaluation of the performance of GenoType® MTBDRplus assay for rapid detection of multi-drug resistant Mycobacterium tuberculosis in Sputum Specimens. Lab Med Online. 2011. 1:19–25.

28. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007. 45:2635–2640.